Top

BMC Complementary Medicine and Therapies

Published in:

Open Access 01-12-2023 | Colorectal Cancer | Research

Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer

Authors: Yongqu Lu, Kangdi Dong, Meng Yang, Jun Liu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2023

Abstract

Background

Evodia rutaecarpa, a traditional herbal drug, is widely used as an analgesic and antiemetic. Many studies have confirmed that Evodia rutaecarpa has an anticancer effect. Here, our study explored the bioactive ingredients in Evodia rutaecarpa acting on colorectal cancer (CRC) by utilizing network pharmacology.

Methods

We clarified the effective ingredients and corresponding targets of Evodia rutaecarpa. CRC-related genes were obtained from several public databases to extract candidate targets. Candidate targets were used to construct a protein–protein interaction (PPI) network for screening out core targets with topological analysis, and then we selected the core targets and corresponding ingredients for molecular docking. Cell proliferation experiments and enzyme-linked immunosorbent assays (ELISAs) verified the anticancer effect of the bioactive ingredients and the results of molecular docking.

Results

Our study obtained a total of 24 bioactive ingredients and 100 candidate targets after intersecting ingredient-related targets and CRC-related genes, and finally, 10 genes—TNF, MAPK1, TP53, AKT1, RELA, RB1, ESR1, JUN, CCND1 and MYC—were screened out as core targets. In vitro experiments suggested that rutaecarpine excelled isorhamnetin, evodiamine and quercetin in the inhibition of CRC cells and the release of TNF-α was altered with the concentrations of rutaecarpine. Molecular docking showed that rutaecarpine could effectively bind with TNF-α.

Conclusion

The pairs of ingredients-targets in Evodia rutaecarpa acted on CRC were excavated. Rutaecarpine as a bioactive ingredient of Evodia rutaecarpamight effectively inhibit the proliferation of CRC cells by suppressing TNF-α.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.CrossRef

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. The Lancet. 2019;394(10207):1467–80.CrossRef

Hanahan D, Weinberg Robert A. Hallmarks of Cancer: the Next Generation. Cell. 2011;144(5):646–74.PubMedCrossRef

Rejhová A, Opattová A, Čumová A, Slíva D, Vodička P. Natural compounds and combination therapy in Colorectal cancer treatment. Eur J Med Chem. 2018;144:582–94.PubMedCrossRef

McQuade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal Cancer chemotherapy: the evolution of treatment and New approaches. Curr Med Chem. 2017;24(15):1537–57.PubMedCrossRef

Vogel A, Hofheinz RD, Kubicka S, Arnold D. Treatment decisions in metastatic Colorectal cancer – beyond first and second line combination therapies. Cancer Treat Rev. 2017;59:54–60.PubMedCrossRef

Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for Colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol/Hematol. 2016;100:209–22.PubMedCrossRef

Baburin I, Varkevisser R, Schramm A, Saxena P, Beyl S, Szkokan P, et al. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo. Pharmacol Res. 2018;131:150–63.PubMedCrossRef

Kumar A, Jaitak V. Natural products as multidrug resistance modulators in cancer. Eur J Med Chem. 2019;176:268–91.PubMedCrossRef

10.

Jiang J, Hu C. Evodiamine: a novel Anti-cancer Alkaloid from Evodia rutaecarpa. Molecules. 2009;14(5):1852–9.PubMedPubMedCentralCrossRef

11.

Park SY, Park C, Park SH, Hong SH, Kim GY, Hong SH, et al. Induction of apoptosis by ethanol extract of Evodia rutaecarpa in HeLa human Cervical cancer cells via activation of AMP-activated protein kinase. Biosci Trends. 2017;10(6):467–76.PubMedCrossRef

12.

Chen T-C, Chien C-C, Wu M-S, Chen Y-C. Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human Ovarian cancer cells. Phytomedicine. 2016;23(1):68–78.PubMedCrossRef

13.

Liao Y, Liu Y, Xia X, Shao Z, Huang C, He J, et al. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in Prostate cancer therapy. Theranostics. 2020;10(8):3366–81.PubMedPubMedCentralCrossRef

14.

Zhang Y, Yan T, Sun D, Xie C, Wang T, Liu X, et al. Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced Colitis. Free Radic Biol Med. 2020;148:33–41.PubMedCrossRef

15.

Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110–1.PubMedCrossRef

16.

Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32(8):1249–66.PubMedCrossRef

17.

Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–90.PubMedCrossRef

18.

Fotis C, Antoranz A, Hatziavramidis D, Sakellaropoulos T, Alexopoulos LG. Network-based technologies for early drug discovery. Drug Discovery Today. 2018;23(3):626–35.PubMedCrossRef

19.

Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13.PubMedPubMedCentralCrossRef

20.

Wang N, Zheng Y, Gu J, Cai Y, Wang S, Zhang F, et al. Network-pharmacology-based validation of TAMS/CXCL-1 as key mediator of XIAOPI formula preventing Breast cancer development and Metastasis. Sci Rep. 2017;7(1):14513.PubMedPubMedCentralCrossRef

21.

Bateman A, Martin M-J, Orchard S, Magrane M, Agivetova R, Ahmad S, et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480–D9.CrossRef

22.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: from Gene Data Mining to Disease Genome sequence analyses. Curr Protocols Bioinf. 2016;54(1):1301–33.CrossRef

23.

Amberger JS, Bocchini CA, Scott AF, Hamosh A. OMIM.org: leveraging knowledge across phenotype–gene relationships. Nucleic Acids Res. 2019;47(D1):D1038–D43.PubMedCrossRef

24.

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence‐based Framework for evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110(3):563–72.PubMedPubMedCentralCrossRef

25.

Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2019;48(D1):D1031–D41.PubMedCentral

26.

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D82.PubMedCrossRef

27.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.PubMedPubMedCentralCrossRef

28.

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–D95.PubMedCrossRef

29.

Berman HM. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235–42.PubMedPubMedCentralCrossRef

30.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009;31(2):455–61.CrossRef

31.

Lee K, Cho S-G, Choi Y, Choi Y-J, Lee G-R, Jeon C-Y, et al. Herbal prescription, Danggui-Sayuk-Ga-Osuyu-Senggang-Tang, inhibits TNF-α-induced epithelial-mesenchymal transition in HCT116 Colorectal cancer cells. Int J Mol Med. 2017;41(1):373–80.PubMed

32.

Ji L, Wu M, Li Z. Rutacecarpine inhibits angiogenesis by targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k signaling pathway. Molecules. 2018;23(8).

33.

Jin SW, Hwang YP, Choi CY, Kim HG, Kim SJ, Kim Y, et al. Protective effect of rutaecarpine against t-BHP-induced hepatotoxicity by upregulating antioxidant enzymes via the CaMKII-Akt and Nrf2/ARE pathways. Food Chem Toxicol. 2017;100:138–48.PubMedCrossRef

34.

Lin JY, Yeh TH. Rutaecarpine administration inhibits cancer cell growth in allogenic TRAMP-C1 Prostate cancer mice correlating with immune balance in vivo. Biomed Pharmacother. 2021;139:111648.PubMedCrossRef

35.

Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–71.PubMedCrossRef

36.

Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2015;12(1):49–62.PubMedPubMedCentralCrossRef

37.

Dörner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11(12):713–24.PubMedCrossRef

38.

Obeed OAA. Increased expression of Tumor necrosis factor-α is associated with advanced Colorectal cancer stages. World J Gastroenterol. 2014;20(48):18390–6.PubMedPubMedCentralCrossRef

39.

Yuan M, Meng W, Liao W, Lian S. Andrographolide antagonizes TNF-α-Induced IL-8 via inhibition of NADPH Oxidase/ROS/NF-κB and Src/MAPKs/AP-1 Axis in Human Colorectal Cancer HCT116 cells. J Agric Food Chem. 2018;66(20):5139–48.PubMedCrossRef

40.

D’Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel Disease: lessons from the past and a look to the future. Gut. 2021;70(7):1396–405.PubMedCrossRef

41.

Alkhayyat M, Abureesh M, Gill A, Khoudari G, Abou Saleh M, Mansoor E, et al. Lower rates of Colorectal Cancer in patients with inflammatory bowel Disease using Anti-TNF therapy. Inflamm Bowel Dis. 2021;27(7):1052–60.PubMedCrossRef

42.

Singh SP, Nongalleima K, Singh NI, Doley P, Singh CB, Singh TR, et al. Zerumbone reduces proliferation of HCT116 colon Cancer cells by inhibition of TNF-alpha. Sci Rep. 2018;8(1):4090.PubMedPubMedCentralCrossRef

43.

Zhang Y, Zhang Y, Zhao Y, Wu W, Meng W, Zhou Y et al. Protection against ulcerative Colitis and Colorectal cancer by evodiamine via anti–inflammatory effects. Mol Med Rep. 2022;25(5).

Title: Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer
Authors: Yongqu Lu
Kangdi Dong
Meng Yang
Jun Liu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-023-04254-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Diallyl disulfide alleviates hypercholesterolemia induced by a western diet by suppressing endoplasmic reticulum stress in apolipoprotein E-deficient mice

Tinospora sinensis (Lour.) Merr alkaloid rich extract induces colon cancer cell death via ROS mediated, mTOR dependent apoptosis pathway: “an in-vitro study”

The step in time study: A feasibility study of a mobile app for measuring walking ability after massage treatment in patients with osteoarthritis

Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells

Tianhuang formula regulates adipocyte mitochondrial function by AMPK/MICU1 pathway in HFD/STZ-induced T2DM mice

Assessment of anticancer, antimicrobial, antidiabetic, anti-obesity and antioxidant activity of Ocimum Basilicum seeds essential oil from Palestine